Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEMOIN
NCT03257618Completed
- Sponsor
- Institut du Cancer de Montpellier
- Start
- Jul 2017
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of temozolomide in diffuse low-grade glioma (LGG), sponsored by Institut du Cancer de Montpellier. Primary endpoints: Proportion of patients that consent to participate in the study at 5 years and Proportion of included patients that will complete the evaluations at baseline, 6 months and 12 months. Started Jul 2017; status: completed.
02
Drugs
temozolomide
03
Conditions
diffuse low-grade glioma (LGG)
Beyond the preview
Go deeper on NCT03257618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03257618.